Role of aromatase inhibitors in the treatment of postmenopausal women with metastatic breast cancer

Current Oncology

Volumn 11, Issue 2, 2004, Pages 41-52

  Eisen, Andrea ^a   Pritchard, K ^b   Johnston, M ^b   Oliver, T ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; FORMESTANE; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; CLINICAL TRIAL; COCHRANE LIBRARY; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG RESPONSE; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MEDICAL SOCIETY; MEDLINE; META ANALYSIS; METASTASIS; NAUSEA; POSTMENOPAUSE; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; WEIGHT GAIN;

EID: 4143146512     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Buzdar A, Howell A. Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer. Clin Cancer Res 2001;7:2620-35.
2. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881-94.
3. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-12.
4. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
5. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-57.
6. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67.
7. Milla-Santos A, Milla L, Rallo L, Solano V. Anastrozole vs. tamoxifen in hormone dependent advanced breast cancer. A phase II randomized trial [abstract]. Breast Cancer Res Treat 2000;64:54.
8. Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9.
9. Dirix L, Piccart MJ, Lohrisch C, et al. Efficacy of and tolerance to exemestane versus tamoxifen in 1st line hormone therapy of postmenopausal metastatic breast cancer patients: a European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn [abstract]. Proc Am Soc Clin Oncol 2001;20:29a.
10. Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A, for the Arimidex Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group. Cancer 1997;79:730-9.
11. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996;32:A404-12.
12. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61.
13. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357-66.
14. Gershanovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Ann Oncol 1998; 9:639-45.
15. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer [abstract]. Proc Am Soc Clin Oncol 2002;22:34a.
16. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase in randomized double-blind trial. The Exemestane Study Group. J Clin Oncol 2000;18:1399-411.
17. Thurlimann B, Paridaens R, Serin D, et al. Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer 1997;33:1767-73.
18. Jones S, Vogel C, Arkhipov A, et al. Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group. J Clin Oncol 1999;17:3418-25.
19. Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase n trial. J Clin Oncol 2000; 18:2234-44.
20. Bonneterre J, Buzdar A, Nabholtz JM, et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92: 2247-58.
21. Nabholtz JM, Bonneterre J, Buzdar A, Robertson JFR, Thurlimann B. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results. Eur J Cancer 2003;39:1684-9.
22. Buzdar AU, Jonat W, Howell A, et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996; 14:2000-11.
23. Messori A, Cattel F, Trippoli S, Vaiani M. Survival in patients with metastatic breast cancer: analysis of randomized studies comparing oral aromatase inhibitors versus megestrol. Anti-cancer Drugs 2000;11:701-6.
24. Weinfurt KP, Wait SL, Boyko W, Schulman KA. Psychosocial quality of life in a phase II trial of letrozole [abstract]. Proc Am Soc Clin Oncol 1998;17:108a.